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Two assays (Liaison, Diasorin; IDEIA, Oxoid) for detection of Borrelia-specific antibodies were
compared. A case–control design using patients with neuroborreliosis (n548), laboratory defined
by a positive Borrelia-specific antibody index in the spinal fluid, was available and was intended to
represent the serological response of disseminated early Lyme borreliosis in general. Serum
samples were obtained from 216 Danish blood donors as controls. By comparing sensitivity and
specificity using pre-specified cut-off values, significant differences were found. However, using
receiver operating characteristic (ROC) curves to optimize and standardize test interpretation, it
was shown that testing with both IDEIA IgG and IgM was comparable to testing with Liaison IgG
alone by comparing the area under the curve of the diagnostically relevant 25% partial ROC curve
(P50.1). When using the Liaison OspC/VlsE IgM assay, the specificity was decreased without a
gain in sensitivity. This study proposes standardizing of reporting by using a control population as
the reference and choosing decision thresholds guided by the risk of false-positive results at 2
and 8%. The sensitivities for IDEIA (IgG and IgM combined) were 85 and 95% and for the
Liaison (VlsE IgG) method were 67 and 96%, respectively. Methods for test evaluation, test
interpretation and statistical testing are presented and discussed. In conclusion, Liaison VlsE IgG
alone and IDEIA IgG/IgM combined showed a high and comparable discriminatory ability to
distinguish serum samples from patients with neuroborreliosis from blood donor controls.
However, cut-off values should be adjusted for a proper comparison.
INTRODUCTION
Lyme borreliosis (LB) is caused by infection with the tick-
borne bacterium Borrelia burgdorferi sensu lato. The most
common clinical manifestation is a rash called erythema
migrans. The disseminated forms of LB are rarer and
include Lyme neuroborreliosis (NB), arthritis, multiple
erythema migrans, lymphocytoma and carditis (Stanek
et al., 2011, 2012). To support clinical diagnosis of dis-
seminated LB, the standard laboratory tests use detection
of the antibody response in blood or spinal fluid. Borrelia-
specific antibody detection is an excellent tool, as sensi-
tivities are high in disseminated disease. The analytical
specificity will be high, as B. burgdorferi possesses diagnos-
tically relevant antigens that are distinct from other related
bacteria. The clinical specificity will also be high, except in
certain subpopulations with continuous exposure to ticks.
As with the use of serology for diagnostic purposes for any
infectious disease, interpretation requires knowledge of the
risk of background immunity, and the fact that sensitivity
may be low in early clinical disease but should be detectable
in all patients by 6–8 weeks after onset of symptoms.
Laboratory support is not necessary or useful for diagnosis
of localized erythema migrans, as some patients may not
develop a detectable antibody response at all.
Studies on diagnostic accuracy for Borrelia-specific IgG and
IgM antibodies are most often presented in the published
literature by counting positive and negative results, without
analysis of the quantitative results. The cut-off recom-
mendation provided by the developer of the assay has been
accepted uncritically in many studies without analysis or
discussion (Busson et al., 2012; Cerar et al., 2010;
Marangoni et al., 2006, 2008; Petersen et al., 2008;
Riesbeck & Hammas, 2007; Tjernberg et al., 2007). It has,
however, been generally recommended that an explanation
of the definition of and rationale for the units and cut-off
values is given when reporting studies of diagnostic
accuracy (Bossuyt et al., 2003a, b). The purpose of the
Abbreviations: AUC, area under the curve; LB, Lyme borreliosis; NB,
neuroborreliosis; NPV, negative predictive value; PPV, positive predictive
value; ROC, receiver operating characteristic.
Supplementary material is available with the online version of this paper.
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current study was to compare the diagnostic accuracy of
two assays that are commonly used in Scandinavian
laboratories (Dessau et al., 2011) and to propose a choice
of cut-off values. Statistical and graphical methods to
report the results are presented and discussed. The aim of
the study was to show that analysis of raw quantitative
measurements is essential to establish conclusions on assay
performance. Additionally, it is proposed that standard-
ization of results of Borrelia serology is necessary using the
controls as a reference population.
METHODS
All test samples were Danish. Serum samples from 48 patients with
a pleocytosis (.36106 per litre) and a positive antibody index in
the cerebrospinal fluid were included. The antibody index was
measured using an IDEIA Lyme Neuroborreliosis IgG/IgM assay
(Oxoid). This assay was developed in Denmark (Hansen, 1994;
Hansen & Lebech, 1991, 1992). The NB samples were collected
consecutively from 2006 to 2010. Serum samples from 216 blood
donors (BDs) were collected in January 2011 as controls. This is
another set of samples from a previous publication (Dessau et al.,
2010b). Forty-four consecutive routine samples from September
2011 were used in this study to illustrate the proposed standardized
reporting.
The Borrelia burgdorferi IDEIA (Oxoid) serum assay is based on
purified native flagella antigen from a cultured strain of Borrelia afzelii
(strain DK1) (Hansen et al., 1988, 1991). This assay was run on a
Siemens BEP2000 automated ELISA instrument. The cut-off value for
this assay was originally adjusted by choosing 2% seropositivity for
IgG or IgM in a population of Danish BDs. The 2% specificity has
not changed over time, as shown in a recent evaluation (Dessau et al.,
2010b).
The Liaison Borrelia IgM Quant and the Borrelia IgG assays
(Diasorin) are based on recombinant OspC and VlsE antigens in
the IgM assay and on VlsE antigens in the IgG assay. These assays run
on a dedicated automated instrument (Liaison). Antigens are coated
on magnetic beads and chemiluminescence is used for signal
detection. The recombinant proteins used as antigens are expressed
in Escherichia coli. This study compared the IDEIA and the Liaison
assays. A second assay, for example an immunoblot, was not
performed, but considerations about threshold adjustment for the
purpose of two-tier testing are presented in the discussion. It should
be noted that many laboratories in Scandinavia do not use a two-tier
procedure on most routine samples (Dessau et al., 2011). This study
focused on describing, comparing and optimizing the discriminatory
power by quantitative analysis.
Definitions. The term decision threshold is used to denote a value
based on the distribution of the measurement values in the BD
controls. This value may be based on a single assay or a combination
of assays scored together.
The term cut-off is used to denote a chosen measurement value (e.g.
calibrated arbitrary units) based on the quantitative results provided
by the laboratory equipment for each assay.
The term specificity in this study is defined as 1 2 (fraction of BDs
who were test positive at a chosen cut-off value or decision
threshold).
The term sensitivity in this study is defined as the fraction of NB
patients who were test positive at a chosen cut-off value or decision
threshold.
Statistics. To assess the statistical significance of the sensitivity and
specificity, a regression method for paired samples was used (Pepe,
2003a). This method may be seen as an extension of the McNemar
test for paired samples. The regression methodology has the
advantage of estimating relative positive fractions with confidence
intervals and multiple tests may be compared. Receiver operating
characteristic (ROC) curves were used for comparison of quantitative
data. Logistic regression was used to combine the results of the four
biomarkers. Comparison of the area under the curve (AUC) was
performed using a bootstrap method (Pepe et al., 2009; Robin et al.,
2011). A concept of cumulative distributions, which is similar to the
ROC curve, is proposed to standardize the results for evaluation and
reporting (Huang & Pepe, 2009). All statistical analyses were
performed using R statistical software (R Development Core Team,
2012). Further details are provided in the supplementary material
(available in JMM Online). Confidence intervals were chosen at 95%.
RESULTS
Qualitative analysis
Traditional qualitative results using the cut-off values
recommended by the manufacturer are shown in Table 1.
For statistical significance, the relative sensitivity and
specificity of each test was compared using the positive
fraction of IDEIA IgG or IgM as reference. The most
sensitive test was Liaison IgG or IgM at 96%, but the
specificity was low at 89%. Liaison IgG alone had a
sensitivity of 94% and the specificity was increased to
94%. Thus, it would seem obvious to choose Liaison IgG
alone and not use IgM. In contrast, IDEIA IgG and IgM
supplemented each other and both had to be used to gain a
sensitivity of 81%, whilst the specificity remained high at
98%. By choosing to use Liaison IgG VlsE alone, the
sensitivity was higher (borderline significant), but the false-
positive rate was three times higher compared with IDEIA.
However, is this an adequate description and comparison
of assay performance? To answer this question, an analysis
of the quantitative data was necessary.
Quantitative analysis
Strip plots as shown in Fig. 1 may be useful, as they show
the individual raw data values and give a visual impres-
sion of the provided cut-off values. In this case, as a
compromise, the many quite negative results mainly in the
BDs are indicated instead by their number. Using Liaison
IgG, all NB samples were reactive, with just two samples in
the indeterminate zone; however, among the 14 reactive
BDs, nine were more strongly reactive. Using Liaison IgM,
there were 13 seropositive BDs. For the IDEIA assay, the
cut-off values were chosen at the upper tail of the
distribution of BD controls. This was in contrast to the
Liaison assays where sensitivity was maximized for IgG. For
Liaison IgM, the choice of cut-off value appeared to be a
difficult compromise to yield at least some sensitivity.
An ROC curve uses ranking of the samples, and thus tests
with different numerical scales can be compared. As shown
in Fig. 2, the results of the 216 BD samples were ranked on
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the x-axis whilst the 48 NB samples were ranked on the y-
axis. ROC curves allow assessment of the discriminatory
power of the biomarker and the choice of cut-off value.
Visual inspection of the ROC curve in Fig. 2(a) showed
that the higher sensitivity of the Liaison IgG and better
specificity of IDEIA IgG or IgM were due mainly to
differences in the cut-off values chosen by the manufac-
turers. When combining IDEIA IgG and IgM in a
regression model, the classifier performance of IDEIA
IgG or IgM appeared slightly more specific compared with
Liaison IgG (Fig. 2b); however, this difference was not
statistically significant (P50.1) when the 75–100% spec-
ificity partial AUCs were compared.
Decision thresholds to maximize specificity are proposed at
2% and to maximize sensitivity at 8% false-positive rate
(Fig. 2b, Table 2). The difficulties in setting a decision
threshold may be appreciated by looking at Fig. 2(b). Had
the threshold been shifted to 3%, the true positive rate of
Liaison and IDEIA would be nearly identical. A small tuning
of the threshold may therefore have a large influence on the
apparent sensitivity. Comparison of the quantitative data
showed that the discriminatory performance of Liaison IgG
was very similar to the combination of IDEIA IgG and IgM.
Another characteristic to assess is the positive predictive
value (PPV) using the chosen decision thresholds. The pre-
test probability of disease has a large impact on test
performance, and low pre-test probabilities may be
problematic (Habbema et al., 2002; Sackett & Haynes,
2002). In Fig. 3(a), the PPV is shown as a function of the
pre-test prevalence of disease using the formula shown in
the supplementary material. Sensitivity had little impact on
PPV compared with specificity when the pre-test preval-
ence was at the lower range of 10% or less. At higher pre-
test prevalence, the sensitivity became more important for
negative predictive value (NPV).
A specificity of 98% was chosen as an important criterion
to set as the cut-off value, as at this level the PPV may reach
50%, even at a low pre-test prevalence around 2%, and a
level of 80% PPV may be reached at 10% pre-test
prevalence. The NPV remained above 95% at the 2 or 10%
pre-test prevalence, regardless of the sensitivity level (Fig.
3b). At a higher pre-test prevalence, the NPV clearly
became very low. Choosing decision thresholds at the
beginning and end of the shoulder of the ROC curve
maximizes the specificity and sensitivity, respectively, with
an area of greater diagnostic uncertainty in between.
Agreement
All correlations were positive (Fig. 4) and the patients with
NB tended to be positive pairwise for the four biomarkers
but with a wide variability in magnitude. The two IgG
assays had a relatively high overall correlation of 0.84,
whereas Liaison IgM has less correlation with the other
three biomarkers. The BDs resided mostly in the negative
cloud (Fig. 4, black circles). Smoothed non-linear regres-
sion lines were added to the graphs to visualize the mean
tendency to positive correlation in each data pair (Fig. 4).
Standardization using controls as the reference
population
It has been argued above that the PPV of a test depends
mainly on the pre-test probability of disease and the
specificity. Thus, it has been proposed to standardize a
biomarker by using the controls as a reference distribution
(Huang & Pepe, 2009). The result of the measurement in a
patient is then expressed as the ‘percentile value’ of the
empirical cumulative distribution in the control group. This
percentile value is exactly the same as the false-positive rate
on the ROC curve. Thus, the methodology is basically the
same, but the presentation is different. The important
implication is that this framework indicates the possibility of
biomarker standardization for reporting of results.
Seropositivity is thus expressed relative to the control
Table 1. The number positive and the relative fraction of seropositivity in 48 patients with NB and 216 BDs for the Liaison and IDEIA
assays
A regression model of relative positive fractions was used to assess statistical significance. For the comparison, IDEIA IgG or IgM was chosen as the
reference and given a value of 1. ‘Indeterminate’ results have been counted as negative.
Assays and combinations Patients with NB (n548) Danish BDs (n5216)
Number
positive (%)
Relative positive fraction
(95% CI)
Number
positive (%)
Relative positive fraction
(95% CI)
IDEIA IgG or IgM 39 (81%) 1 4 (2%) 1
Liaison IgG or IgM 46 (96%) 1.20 (1.0–1.4)* 24 (11%) 6.00 (2.12–17)*
IDEIA IgG 21 (44%) 0.54 (0.38–0.76)* 1 (0.5%) 0.25 (0.03–2.22)
IDEIA IgM 29 (60%) 0.74 (0.57–0.97)* 3 (1%) 0.75 (0.17–3.31)
Liaison IgG 45 (94%) 1.15 (0.99–1.35) 14 (6%) 3.50 (1.17–10.0)*
Liaison IgM 22 (46%) 0.56 (0.40–0.79)* 13 (6%) 3.25 (1.08–9.81)*
*95% confidence intervals (CI) greater or smaller than 1 are significant.
Borrelia serology cut-off
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distribution. With regard to the present data, the 48 NB
patients had a high reactivity compared with the healthy
background population (Fig. 5) represented by the BDs.
The Liaison IgG assay contained 181 measurements
censored below 5 units. This gave 181 ties in the
cumulative distribution and the percentile values could
only start at 84% (Fig. 5). The observations at or below the
75% percentile value were censored in the plot anyway, as
they had little diagnostic value. Thus, the results of the
different assays were conveniently standardized and
expressed on the same scale. To illustrate standardized
reporting (Fig. 5), 44 consecutive routine patients of
unknown clinical status were analysed. Ten (22%) were
Liaison IgG positive and four (9%) were IDEIA IgG and
IgM positive above the 92% percentile (McNemar’s test
P50.04). This can be compared with Fig. 1 where the four
different plots each had their own scale of measurement
and levels of cut-offs. Furthermore, the scale (y-axis on
Fig. 5) is clinically informative as the risk of false or natural
background seroreactivity is inherent.
DISCUSSION
Using the pre-specified cut-off values, the present study
falls within the range of sensitivities found in previous
studies. In two studies using the Liaison assay with a total
of 28 and 34 patients with NB, the reported sensitivities
were 7 and 56% for IgM and 86 and 74% for IgG,
respectively (Cerar et al., 2006, 2010). This is similar to the
present study where 46% of NB patients were found to be
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Fig. 1. Strip plots of the data on a natural log scale used for the subsequent analysis. The very low data-values are not plotted
but the number is shown below for each category. The cut-offs specified by the manufacturer are shown with the indeterminate
values between the horizontal broken lines.
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Liaison IgM positive and 94% IgG positive. In the first
study, only two of 28 patients were found to be IgM positive,
but this can be explained as the NB patients were not defined
and the IgM assay was a previous version of the assay
containing only OspC and not VlsE as antigen. In previous
publications with NB patients, the sensitivity and specificity
of the IDEIA assay ranged from 44 to 84% (median 65%)
for IgG and from 41 to 74% (median 57%) for IgM (Bennet
et al., 2008; Cerar et al., 2010; Dessau et al., 2010b; Ekerfelt
et al., 2004; Hansen & Lebech, 1991, 1992; Lebech et al.,
2000). In the present study, the sensitivity of IgG was 44%
and of IgM was 60%, which is within the range of published
studies. In this study, 81% of NB patients were IgG or IgM
positive, which is comparable to the published sensitivities
of 76–93% (median 88%), which confirms the utility of
combining IDEIA IgG and IgM (Bennet et al., 2008; Dessau
et al., 2010b; Hansen & Lebech, 1992; Lebech et al., 2000).
In this group of 48 patients with NB, the VlsE-based IgG
antigen alone was sensitive enough to render IgM testing
unnecessary. ‘Single-tier’ testing with the C6 fragment of
VlsE has been found to be comparable to various other test
combinations in a study based on North American patients
(Wormser et al., 2013). A multicenter European study
evaluating the Siemens Enzygnost assay found that, after
addition of recombinant VlsE, an increased IgG sensitivity
was observed, mainly in the IgM-positive samples (Hunfeld
et al., 2005).
Agreement between two assays using different Borrelia-
specific antigens should not be expected, only a tendency to
co-reactivity. There is no known biological mechanism
to co-regulate development of individual antibodies to
different specific antigens. In contrast, variable antibody
expression both in time and in magnitude should be
expected due to complex regulation of antibody responses
with feedback regulation (Hjelm et al., 2006). In this study,
some positive correlation was found but certainly no linear
relationship. The data corroborate an assumption of
variability concerning antibody responses in patients with
LB. There is heterogeneity of the humoral response to
different target antigens in the same patient and between
patients after bacteraemia with Staphylococcus aureus
(Verkaik et al., 2010). This natural variation among
biomarkers detecting antibodies to the same disease has
been found previously and is troublesome for proficiency
testing programmes and assay comparison (Ang et al.,
2011; Brandenburg et al., 2011; Mu¨ller et al., 2012;
Robertson et al., 2000). It is possible that the detection
system containing somewhat denatured antigens will
contribute to the variability in signal strength. This means
that a given patient may not necessarily express detectable
antibodies to both the flagella and the VlsE antigen at the
same time. However, a tendency for a stronger response to
most immunodominant antibodies as a function of disease
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Fig. 2. Partial ROC curves up to a 25% rate of seropositivity in the BDs. (a) Individual assays with the position of cut-off points
as recommended by the manufacturers. (b) Combination of IDEIA IgG and IgM using a logistic regression model compared with
Liaison IgG. The partial AUCs in (b) are 23.8 and 22.7% (P50.10, bootstrap method). Cut-off values are proposed at 2 and
8% false-positive rate (dashed vertical lines).
Table 2. Sensitivity using decision thresholds set at a false-
positive rate of 2 and 8%
With regard to IDEIA, the decision thresholds are the probability of
having NB as predicted from the logistic model. For Liaison, the
thresholds are the units directly provided by the automated
equipment. The lower cut-off unit of 8 is close to the value of 10
proposed by the manufacturer.
IDEIA IgG and IgM Liaison VlsE IgG
NB (n548) 85% 95% 67% 96%
Chosen specificity 98% 92% 98% 92%
Cut-off point 0.52 0.1 117 8
Borrelia serology cut-off
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development (time, dissemination and intensity of the
inflammatory response) could be expected. In this study,
we did not have clinical data on the patients with NB. It
is likely that these patients had variability in clinical
presentation concerning the duration of disease and
severity. This variability was evident in the data, as shown
in the matrix plot (Fig. 4).
ROC curves provide a description of performance and
may be used for comparing tests and for guiding the
choice of threshold for clinical applications (Pepe,
2003b). In this study, a partial 25% AUC was chosen as
a clinically relevant summary measure. The choice of
the restricted region may be arguable, but in this study it
was chosen to safely include the maximal obtainable
specificity.
ROC analysis has been used occasionally for evaluating
Borrelia assays (Burbelo et al., 2010; Huppertz et al., 1998;
Porwancher et al., 2011; Wagner et al., 2011). The author
has not been able to find previously published papers
discussing the choice of cut-off for detecting Borrelia-
specific antibodies for clinical application. Major reviews
do not consider this issue and just list the range of
sensitivities and specificities (Aguero-Rosenfeld, 2008;
Aguero-Rosenfeld et al., 2005). As shown in the present
study, this heterogeneity could mainly be explained by the
choice of cut-off value. The cut-off point of the IDEIA was
originally established as a decision threshold by defining
that 98% of Danish healthy controls should be seronega-
tive (Dessau et al., 2010b). The strategy of cut-off
determination for the Liaison assay is not documented,
but it appears from the present study that sensitivity was
maximized for IgG and a compromise between sensitivity
and specificity was chosen for IgM. The statistical
comparison of ROC curves gives a gross impression if
the AUC, in this case the 25% partial AUC, is different in
the two datasets. As the curves were nearly parallel (e.g.
without crossover), this model should be fairly valid for
testing of statistical significance.
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Fig. 4. Pairwise matrix plot of test results with locally weighted
polynomial regression lines (red) and correlations in the upper
diagonal. The natural logarithm of the calibrated ELISA units was
used. The 48 patients with NB are designated with red circles and
BD patients with black circles. Correlations were calculated for the
whole dataset containing both the NB and BD data. Smoothed
non-linear regression lines are indicated as red lines.
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The concept of standardizing using a disease-negative or
normal population as reference and expressing the
‘abnormal’ result relative to this distribution is a basic
issue concerning the use of any biomarker for diagnostic
purposes (Huang & Pepe, 2009; Sackett & Haynes, 2002).
Using the control group to determine the decision
threshold is practical, as samples from patients without
LB are readily available in large numbers in any diagnostic
laboratory. In this study, we used BDs routinely screened as
healthy at the time of sampling. Thus, the lowest possible
background seroreactivity for both IgG and IgM should be
expected especially when sampled during winter, as in this
case. More reasons to base the decision threshold mainly
on the distribution of a non-LB control group are that
samples are quite conveniently available in larger numbers
and, if chosen locally, will represent the seroreactivity in
the adult population.
The choice of decision threshold is intended to guide the
clinician in diagnosing a patient with active Borrelia
infection. The author would like to propose two decision
thresholds for use in different clinical situations where LB
is suspected:
1. Cut-off at 98% specificity for patients with longer
(e.g. .30 days) duration of clinical disease considering
the IgG response alone or combined with IgM as
appropriate according to recommendations (Stanek
et al., 2011), and in any case where the pre-test
probability of LB is low. This applies to the ‘rule out’
situation in patients where the clinical suspicion of LB
is low.
2. A lower decision threshold at 92% specificity for
patients with shorter duration of clinical disease and
where the clinical presentation is typical of LB,
consistent with case definitions and when the pre-test
probability is higher than 10%. Both IgG and IgM
response should be considered or VlsE IgG alone.
This could make clinical sense as the diagnostic situations
differ as a function of disease development. Between these
two decision thresholds is the shoulder of the ROC curve
where the assays are neither safely negative nor safely positive.
Thus, this is the clinically important indeterminate or grey-
zone interval. The more specific cut-off could be applied
when diagnosing acrodermatitis or arthritis where high levels
of antibody reactivity are expected. However, when diagnos-
ing earlier diseases like lymphocytoma or Borrelia carditis,
the lower measurement values could be evaluated as positive,
but the clinician has to be aware of an 8% positive rate in the
background population. If an ELISA is to be used as a
screening assay before a second test, the lower cut-off value
should probably always be used. However, it is beyond the
scope of this study to optimize a two-tier combination. It is
probably more important to optimize the co-interpretation
of IgG and IgM as proposed in the present study and in
a previous study (Dessau et al., 2010b). However, the
principles of data analysis presented in this study could serve
as a basis for adding more biomarkers to the test strategy.
It is relevant to consider a combination of test results when
choosing decision thresholds, as most laboratories perform
both IgG and IgM testing and some perform supplement-
ary tests such as immunoblotting. It is possible that cut-offs
may have to be adjusted to a representative local or
regional serum panel of controls as background immunity
may vary. Another possibility is to avoid using thresholds.
The author has previously recommended reporting quan-
titative measurements with probability thresholds (risk
scores) for guidance (Dessau et al., 2010b).
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Fig. 5. Percentile values of 48 patients with NB and 44 routine patients standardized using the cumulative distribution of BD
controls as a reference. The graph shows the percentile values of 75% and above corresponding to the 25% partial ROC
curve in Fig. 2. The Liaison IgG assay had a truncation of the negative results at 5 units. Thus, 181 of the 216 (84%) BDs had a
result of 5 units compared with only one of the NB patients (see Fig. 1). IDEIA is the prediction using the logistic regression
model. The 92 and 98% decision thresholds are shown as horizontal dashed grey lines.
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This study had a case–control design. This design was
chosen because of the practical availability of samples and a
lower risk of misclassification. In principle, this is not ideal,
as it is not representative for a consecutive cohort of
patients. Cases of NB were included by virtue of being
reactive to the flagella antigen in the IDEIA antibody index
test (and cerebrospinal pleocytosis). Thus, the sensitivity of
IDEIA could be overestimated compared with Liaison.
Thus, the overall sensitivity could be overestimated. In the
already cited Slovenian study, the inclusion criteria for NB
were a current or recent erythema migrans and spinal fluid
pleocytosis (Cerar et al., 2010). In this study, the sensitivity
was found to be lower in both Liaison (79%) and IDEIA
(59%) for IgG or IgM. However, the selection of cases is in
principle not so important for the choice of cut-off or
estimated predictive values. Even if the IDEIA assay is less
sensitive than estimated in the present study, the impact on
PPV or NPV would be small, as discussed. We can assume
that patients without Borrelia-specific antibodies would
belong to a group with lower values compared with
Borrelia patients who have converted to higher values, and
that few patients are caught in the phase of conversion.
Thus, the means and variation of the two distributions
would not be affected by selection bias in the NB group and
the choice of decision threshold should not be changed.
Selection bias would affect the number of persons counted
above and below the decision threshold.
Other manifestations of LB (e.g. Borrelia carditis, lympho-
cytoma) are too rare to collect serum panels within a
practical time-span. Thus, it is necessary to use patients
with NB instead of patients with other disseminated
clinical manifestations of LB for test evaluations.
Hypothetically, antibody detection should depend more
on the disease development in general (duration and extent
of inflammation) and less on the anatomical site as such,
and the dynamics of the humoral immune response in
patients with NB should be similar to patients with early
disseminated LB involving other organ systems.
The risk of including non-LB patients should be low. The
IDEIA antibody index test is documented to be very specific
and sensitive in the Danish context and may be considered a
reference standard based on evaluation of a large panel of
well-characterized patients with NB (Dessau et al., 2010b;
Hansen, 1994; Hansen & Lebech, 1992). In a highly endemic
area like Slovenia, this index assay was 90% specific (Cerar
et al., 2010). In this study, the NB samples were collected as a
part of the consecutive clinical routine.
Pre-test prevalence is more important for the predictive
value compared with sensitivity and specificity, as shown in
Fig. 3 (Fletcher et al., 1996). This emphasizes that LB
diagnosis should be based on the clinical presentation and
an assessment of tick-exposure risk and not on laboratory
results alone (Stanek et al., 2011). One reason is that pre-
test prevalence, depending on the individual clinical
situation, will vary over a wide range from much less than
1% to near 100% diagnostic certainty.
Detection of serum antibodies has been recommended for
diagnosing disseminated cases of LB except for erythema
migrans and NB (Stanek et al., 2011). However, Borrelia
serology is widely used in various clinical situations where
the clinician may instead want to rule out LB and where the
pre-test probability of LB is low (Dessau et al., 2010a). This
argues for the importance of selecting decision thresholds
based on the distribution of LB-negative controls.
CONCLUSION
The study has shown the importance of assessing
quantitative data so that false conclusions concerning
performance of the test antigens are not reached. It is
important to assess the cut-off strategy independently and
not just accept the provided thresholds. A newer
development is the availability of tests allowing the
assessment of statistical significance when comparing
ROC curves (Pepe et al., 2009; Robin et al., 2011). The
use of non-LB controls (for example BDs) as a reference
population to standardize interpretation of results using
empirical percentile values instead of measurement units
has been discussed.
It was shown that the Liaison IgG assay using recombinant
VlsE antigen had an excellent discriminatory capability
comparable to the combination of IDEIA IgG and IgM
when evaluated in a serum panel from patients with NB
compared with Danish BDs. Two clinical decision thresh-
olds have been proposed defined by the specificity: a
specificity of 98% for patients with a longer duration of
clinical disease, and an intermediate seroreactivity between
the lower 92% and upper 98% decision threshold in
clinical situations where there is suspicion of early LB and
where the pre-test probability of LB is high at around 10%
or more.
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